Cytolytic pathways in haematopoietic stem-cell transplantation

Nature Reviews Immunology

Volumn 2, Issue 4, 2002, Pages 273-281

  Van den Brink, Marcel R M ^a   Burakoff, Steven J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; FAS ANTIGEN; FAS LIGAND; GRANZYME; PERFORIN; UNCLASSIFIED DRUG;

ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; BONE MARROW PURGING; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL TRANSFER; CONDITIONING REGIMEN; CYTOLYSIS; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SCLERODERMA; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; ALLOTRANSPLANTATION; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; NEOPLASM; STEM CELL;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; STEM CELLS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036550199     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri775     Document Type: Review

References (96)

1. Appelbaum, F. R. Haematopoietic cell transplantation as immunotherapy. Nature 411, 385-389 (2001). Describes the 'paradigm shift' in haematopoietic stem-cell transplantation from a platform for high-dose chemotherapy/radiation therapy to immunotherapy.
2. Ferrara, J. L. Levy, R. & Chao, N. J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant 5, 347-356 (1999). Provides a comprehensive, well-written analysis of our current understanding of the complex pathophysiology of graft-versus-host disease.
3. Vogelsang, G. B. Acute and chronic graft-versus-host disease. Curr. Opin. Oncol. 5, 276-281 (1993).
4. Truitt, R. L. & Johnson, B. D. Principles of graft-vs.-leukemia reactivity. Biol. Blood Marrow Transplant. 1, 61-68 (1995).
5. Goulmy, E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 157, 125-140 (1997)
6. McSweeney, P. A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001).
7. Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041-2050 (1995).
8. Kernan, N. A. in Hematopoietic Cell Transplantation (eds Forman, S. J., Blume, K. G. & Thomas, E. D.) 186-196 (Blackwell Science, Malden, Massachusetts, 1999).
9. Weiden, P. L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
10. Kagi, D. et al. Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity. Science 265, 528-530 (1994).
11. Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652 (1994). References 10 and 11 used mice that are deficient for perforin or FasL to show that the perforin and FasL cytolytic pathways are responsible for most of the cytolytic activity of T cells.
12. Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).
13. Suzuki, I. & Fink, P. J. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187, 123-128 (1998).
14. Kishimoto, H., Surh, C. D. & Sprent, J. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med 187, 1427-1438 (1998)
15. Kagi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice, Nature 369, 31-37 (1994).
16. Matloubian, M. et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 73, 2527-2536 (1999).
17. Smyth, M. J., Godfrey, D. I. & Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunol. 2, 293-299 (2001).
18. Van den Broek, M. E. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781-1790 (1996).
19. + T cells clear influenza virus by perforin- or Fas-dependent processes. J. Immunol. 159, 5197-5200 (1997).
20. Straus, S. E. et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194-200 (2001).
21. Davidson, W. F., Giese, T. & Fredrickson, T. N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas-ligand interactions. J. Exp. Med. 187, 1825-1838 (1998).
22. Spaner, D., Raju, K., Rabinovich, B. & Miller, R. G. A role for perforin in activation-induced T-cell death in vivo: increased expansion of allogeneic perforin-deficient T cells in SCID mice. J. Immunol. 162, 1192-1199 (1999).
23. Sambhara, S. et al. Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice. Cell. Immunol. 187, 13-18 (1998).
24. Peng, S. L., Moslehi, J., Robert, M. E. & Craft, J. Perforin protects against autoimmunity in lupus-prone mice. J. Immunol. 160, 652-660 (1998).
25. Lee, S. et al. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant. 20, 883-888 (1997)
26. + T-cell activation and IFN-γ production. J. Immunol. 161, 2848-2855 (1998).
27. Wasem, C. et al. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J. Immunol. 167, 2936-2941 (2001).
28. Das, H. et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br. J. Haematol. 104, 795-800 (1999).
29. Kanda, Y. et al. Increased soluble Fas-ligand in sera of bone-marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 22, 751-754 (1998)
30. Liem, L. M. et al. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 91, 1464-1468 (1998).
31. Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H. & Tsohopp, J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183, 657-661 (1996).
32. Via, C. S., Nguyen, P., Shustov, A., Drappa, J. & Elkon, K. B. A major role for the Fas pathway in acute graft-versus-host disease. J. Immunol. 157, 5387-5393 (1996).
33. Baker, M. B., Altman, N. H., Podack, E. R. & Levy, R. B. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med 183, 2645-2656 (1996). References 31-33 (and reference 37) used mouse models of HSCT and mice that were deficient for FasL, perforin or granzyme B; they were the first to show the importance of the FasL and perforin-granzyme cytolytic pathways in the development of GVHD.
34. Baker, M. B., Riley, R. L., Podack, E. R. & Levy, R. B. Graft-versus-host-disease-associated lymphoid hypoplasia and B-cell dysfunction is dependent upon donor T-cell-mediated Fas-ligand function, but not perforin function. Proc. Natl Acad. Sci. USA 94, 1366-1371 (1997).
35. Graubert, T. A., DiPersio, J. F., Russell, J. H. & Ley, T. J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100, 904-911 (1997).
36. Teshima, T. et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104, 317-325 (1999).
37. Graubert, T. A., Russell, J. H. & Ley, T. J. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 87, 1232-1237 (1996)
38. Schmaltz, C. et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97, 2886-2895 (2001).
39. Tsukada, N., Kobata, T., Aizawa, Y., Yagita, H. & Okumura, K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93, 2738-2747 (1999). References 37-39 (and reference 52) showed, in mouse HSCT models, the differential use of the FasL and perforin cytolytic pathways by donor T cells in GVHD and GVT activity.
40. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64, 571-576 (1997).
41. Shustov, A. et al. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J. Clin. Invest. 106, R39-R47 (2000).
42. Miwa, K. et al. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int. J. Immunol. 11, 925-931 (1999).
43. Mori, T. et al. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host-reaction-associated myelosuppression. Blood 92, 101-107 (1998).
44. Hattori, K. et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-α antibodies on acute graft-versus-host disease pathologies. Blood 91, 4051-4055 (1998). This study showed, by the administration of neutralizing antibodies in mouse HSCT models, the specific role of the FasL and TNF pathways in the development of target-organ GVHD.
45. Van den Brink, M. R. et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J. Immunol. 164, 469-480 (2000).
46. Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3, 409-413 (1997).
47. Piguet, P. F., Grau, G. E., Allet, B. & Vassalli, P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166, 1280-1289 (1987).
48. Herve, P. et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor-α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79, 3362-3368 (1992).
49. Lin, T. et al. Fas-ligand-mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J. Clin. Invest. 101, 570-577 (1998).
50. Stuber, E., Buschenfeld, A., von Freier, A., Arendt, T. & Folsch, U. R. Intestinal crypt cell apoptosis in murine acute graft-versus-host disease is mediated by tumour necrosis factor-α and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Gut 45, 229-235 (1999).
51. Pan, L. et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 93, 4071-4078 (1999).
52. Hsieh, M. H. & Korngold, R. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 98, 1047-1055 (2000).
53. Hattori, K. et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 90, 542-548 (1997).
54. Ito, M. & Shizuru, J. A. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biol. Blood Marrow Transplant. 5, 357-368 (1999).
55. + T-cell effectors that are responsible for causing bone-marrow graft rejection are sensitive to cytotoxicity that is mediated by both perforin- and FasL-dependent mechanisms, and also, that donor T cells must have at least one functional cytotoxic mechanism to prevent allogeneic marrow graft rejection.
56. Baker, M. B., Podack, E. R. & Levy, R. B. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol. Blood Marrow Transplant. 1, 69-73 (1995).
57. Iwasaki, T. et al. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas-ligand interactions but this does not explain the effect of GVHD on donor cells. Cell. Immunol. 197, 30-38 (1999).
58. Blazar, B. R. et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J. Immunol. 165, 4901-4909 (2000).
59. Lan, F., Zeng, D., Huie, P., Higgins, J. P. & Strober, S. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-αβ. Blood 97, 3458-3465 (2001).
60. + CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13, 507-515 (2000).
61. Van den Brink, M. R. et al. Fas-ligand-deficient gld mice are more susceptible to graft-versus-host disease. Transplantation 70, 184-191 (2000).
62. Jiang, Z., Jones, M. & Levy, R. B. FasL and perforin cytotoxically impaired donor T cells induce GVHD in TNF receptor 1 (p55)-knockout MHC I/II mismatched recipients. Biol. Blood Marrow Transplant 7, 76 (2001).
63. Jiang, Z., Podack, E. & Levy, P. B. Major-histocompatibility-complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98, 390-397 (2001).
64. Ware, C. F., VanArsdale, T. L., Crowe, P. D. & Browning, J. L. The ligands and receptors of the lymphotoxin system. Curr Top. Microbiol. Immunol. 198, 175-218 (1995).
65. + T-cell killing of antigen-presenting macrophages. J. Immunol. 164, 2897-2904 (2000).
66. Thomas, W. D. & Hersey, P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T-cell killing of target cells. J. Immunol. 161, 2195-2200 (1998).
67. + T-cell-mediated cytotoxicity. J. Immunol. 162, 2639-2647 (1999).
68. Horowitz, M. M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
69. Slavin, S. et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87, 2195-2204 (1996)
70. Johnson, B D., Drobyski, W. R. & Truitt, R. L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11, 329-336 (1993).
71. Mackinnon, S. et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T-cell dose important in determining biological response? Bone Marrow Transplant. 15, 591-594 (1995).
72. Giralt, S. et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86, 4337-4343 (1995).
73. Alyea, E. P. et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91, 3671-3680 (1998).
74. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60, 355-361 (1995).
75. Martin, P. J. et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 94, 2192-2199 (1999).
76. + T-cell depletion does not prevent graft-versus-host disease. Transplantation 66, 138-141 (1998).
77. Koh, M. B., Prentice, H. G. & Lowdell, M. W. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant 23, 1071-1079 (1999).
78. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Sharpe, A. H. & Vallera, D. A. Opposing roles of CD28-B7 and CTLA-4-B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162, 6368-6377 (1999).
79. Guinan, E. C. et al. Transplantation of anergic histoincompatible bone marrow allografts N. Engl. J. Med. 340, 1704-1714 (1999).
80. + donor T cells fail to induce experimental acute graft-versus-host disease J. Immunol. 155, 585-593 (1995).
81. + lymphoid engraftment. J Immunol. 152, 1004-1013 (1994).
82. Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018-1023 (2000).
83. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724 (1997)
84. Cooke, K. R. et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 107, 1581-1589 (2001).
85. Krammer, P. H. CD95's deadly mission in the immune system. Nature 407, 789-795 (2000).
86. Watanabe-Fukunaga, P. et al. The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274-1279 (1992).
87. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317-322 (1996)
88. Shresta, S., Pham, C. T., Thomas, D. A., Graubert, T. A. & Ley, T. J. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10, 581-587 (1998).
89. Siegel, R. M. et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357 (2000).
90. Chan, F. K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354 (2000).
91. Lowin, B., Beermann, F., Schmidt, A. & Tschopp, J. A null mutation in the perforin gene impairs cytolytic T-lymphocyte and natural-killer-cell-mediated cytotoxicity. Proc Natl Acad. Sci. USA 91, 11571-11575 (1994).
92. Liu, C. C., Persechini, P. M. & Young, J. D. Perforin and lymphocyte-mediated cytolysis. Immunol. Rev. 146, 145-175 (1995).
93. French, L. E. & Tschopp, J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J. Exp. Med. 190, 891-894 (1999).
94. Hsieh, M. H., Patterson, A. E. & Korngold, R. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. Biol. Blood Marrow Transplant. 6, 231-240 (2000).
95. Motyka, B. et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T-cell-induced apoptosis. Cell 103, 491-500 (2000).
96. Jones, M., Komatsu, M. & Levy, R. B Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol. Blood Marrow Transplant 6, 456-464 (2000).